17 32

Cited 0 times in

Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?

Authors
 Philipp Gauckler  ;  Jae Il Shin  ;  Federico Alberici  ;  Vincent Audard  ;  Annette Bruchfeld  ;  Martin Busch  ;  Chee Kay Cheung  ;  Matija Crnogorac  ;  Elisa Delbarba  ;  Kathrin Eller  ;  Stanislas Faguer  ;  Kresimir Galesic  ;  Siân Griffin  ;  Zdenka Hrušková  ;  Anushya Jeyabalan  ;  Alexandre Karras  ;  Catherine King  ;  Harbir Singh Kohli  ;  Rutger Maas  ;  Gert Mayer  ;  Sergey Moiseev  ;  Masahiro Muto  ;  Balazs Odler  ;  Ruth J Pepper  ;  Luis F Quintana  ;  Jai Radhakrishnan  ;  Raja Ramachandran  ;  Alan D Salama  ;  Mårten Segelmark  ;  Vladimír Tesař  ;  Jack Wetzels  ;  Lisa Willcocks  ;  Martin Windpessl  ;  Ladan Zand  ;  Reza Zonozi  ;  Andreas Kronbichler  ;  RITERM study group 
Citation
 AUTOIMMUNITY REVIEWS, Vol.19(11) : 102671, 2020-11 
Journal Title
 AUTOIMMUNITY REVIEWS 
ISSN
 1568-9972 
Issue Date
2020-11
Keywords
Focal segmental glomerulosclerosis ; Infections ; Long-term remission ; Minimal change disease ; Nephrotic syndrome ; Rituximab
Abstract
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations.
Files in This Item:
T202004765.pdf Download
DOI
10.1016/j.autrev.2020.102671
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Shin, Jae Il(신재일) ORCID logo https://orcid.org/0000-0003-2326-1820
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180441
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links